Datasea Achieves Breakthrough in Acoustic Technology, Accelerating Billion-Dollar Commercialization in Healthcare
DTSS' Acoustic innovation Addresses the Healthcare Application Market Projected to Exceed $100 Billion in China and Approach $90 Billion Globally by 2030 BEIJING, Aug. 18, 2025 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), a Nevada-based technology enterprise specializing in advanced acoustic high-tech products and AI multimodal digital solutions,...
Mabwell to Present the Clinical Data of 9MW2821 in Cervical Cancer as Focused Plenary Oral Presentation at 2024 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer
SHANGHAI, March 8, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that it will present the clinical study results on the efficacy and safety of the novel Nectin-4-targeting ADC 9MW2821 for patients with recurrent or metastatic cervical cancer as focused plenary oral presentation at the Society of Gynecologic Oncology (SGO) annual meeting on...
Laekna Releases 2023 ESG Report
SHANGHAI and WARREN, N.J., April 29, 2024 /PRNewswire/ -- Laekna, Inc. (2105.HK), a science-driven, clinical-stage biotechnology company, released its 2023 Environmental, Social and Governance (ESG) report since its listing on the HKEX on June 29, 2023. Laekna means "to cure, to heal", underscores the company's fundamental mission of healing and caring for patients since its inception. Laekna strives for...
First product based on LTS Sorrel™ wearable drug delivery platform launched in the US
ANDERNACH, Germany, Feb. 28, 2024 /PRNewswire/ -- LTS LOHMANN Therapie-Systeme AG ("LTS"), a leading pharmaceutical technology company, announced today that its customer Coherus BioSciences, Inc ("Coherus") has launched its UDENYCA® on-body injector (OBI) utilizing the LTS Sorrel™ wearable drug delivery platform.) UDENYCA® (pegfilgrastim-cbqv) is a biosimilar pegfilgrastim administered the day after chemotherapy to decrease the incidence of infection as manifested...
A Brainwave Technology from Hyundai Mobis Proven to Reduce Drowsiness and Inattentive Driving by Up to 1/3
M.Brain, the world's first brainwave technology developed last year, proven to be effective in a pilot application. Cuts down drowsiness after meals by 30% and on highways by 20% max. Also, reduces time taken to recover attention by three times. Hyundai Mobis secures competitiveness with in-vehicle healthcare in advance by obtaining massive amounts of evidential...
JediCare Medical has announced successful completion of its first-in-human feasibility study of the world’s first-of-its-kind Pulmonary Nodule Percutaneous Sphere Resection
SHANGHAI, April 30, 2025 /PRNewswire/ -- JediCare Medical Technology Co., Ltd. a Shanghai, China based company ("the Company"), jointly with West China Hospital of Sichuan University, recently announced the successful completion of first-in-human ("FIH") feasibility study of its innovative, propriety pulmonary nodule excision device—the "Pulmonary Nodule Grabbing System", the world's first-of-its-kind pulmonary nodule percutaneous sphere resection device. The prospective,...
Nippon Express Group’s MD Logistics Opens “Garner 2000 Pharmaceutical Logistics Center” in North Carolina, U.S.
TOKYO, April 21, 2023 /PRNewswire/ -- MD Logistics, LLC (hereinafter "MD"), a group company of NIPPON EXPRESS HOLDINGS, INC., held an opening ceremony on March 23 for the Garner 2000 Pharmaceutical Logistics Center, a dedicated pharmaceutical warehouse established in Garner in the U.S. state of North Carolina in January this year. NIPPON EXPRESS logo: https://kyodonewsprwire.jp/img/202304184990-O1-hPPV3b7z Opening ceremony: https://kyodonewsprwire.jp/prwfile/release/M103866/202304184990/_prw_PI2fl_K2l3XlYL.jpg North...
RemeGen’s Pioneering RC88 Receives IND Approval from US FDA for Platinum-Resistant Recurrent Ovarian Cancer Treatment
YANTAI, China, Dec. 28, 2023 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, announced that its independently developed mesothelin-targeting antibody-drug conjugate (ADC), RC88, has recently received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for Phase II clinical trials in the...
Kidney Dialysis Foundation Unveils First In-Person ‘Got To Walk 2023: Illuminating Life’ Event To Raise Funds For Needy Kidney Patients
Illuminating the lives of needy kidney patients by walking together for a good cause. SINGAPORE, Sept. 11, 2023 /PRNewswire/ -- The Kidney Dialysis Foundation (KDF) is thrilled to unveil the inaugural in-person edition of the 'Got To Walk 2023: Illuminating Life' walkathon, a flagship fundraising event of KDF for needy kidney...
BIO Asia-Taiwan 2022 concludes, marking another successful edition of the region’s biggest bioindustry-focused conference and exhibition
Exhibition visitors surpass 100,000 people over 4 days BIO Asia–Taiwan success a testament to Taiwan's booming biotechnology industry TAIPEI, Aug. 8, 2022 /PRNewswire/ -- BIO Asia–Taiwan 2022, held at the TaiNEX 2 Exhibition Center, Nangang, Taipei, from 27-31 July, came to a successful conclusion on Sunday, 31st of July. Held in an innovative onsite-online format to encourage international participation,...
